Biotherapies developed and manufactured in France in compliance with good practices
Clinical studies based on real animal treatments
Easy to use products, delivered solely by veterinarians
Précédent
Suivant
Biotherapies developed and manufactured in France in compliance with good practices
Clinical studies based on real animal treatments
Easy to use products, delivered solely by veterinarians
Précédent
Suivant

14 – Use of adipose-derived mesenchymal stem cells in keratoconjunctivitis sicca in a canine model.

Villatoro AJ, Ferna?ndez V, Claros S, Rico- Llanos GA, Becerra J, Andrades JA. Biomed Res Int. 2015.

Keratoconjunctivitis sicca (KCS) or dry eye disease (DED) is an immune-mediated multifactorial disease, with high level of prevalence in humans and dogs. Our aim in this study was to investigate the therapeutic effects of allogeneic adipose-derived mesenchymal stromal cells (Ad-MSCs) implanted around the lacrimal glands in 12 dogs (24 eyes) with KCS, which is refractory to current available treatments. Schirmer tear test (STT) and ocular surface integrity were assessed at 0 (before treatment), 3, 6, and 9 months after treatment. Average STT values and all clinical signs showed a statistically significant change (P < 0.001) during the follow-up with reduction in all ocular parameters scored: ocular discharge, conjunctival hyperaemia, and corneal changes, and there were no signs of regression or worsening. Implanted cells were well tolerated and were effective reducing clinical signs of KCS with a sustained effect during the study period. None of the animals showed systemic or local complications during the study. To our knowledge, this is the first time in literature that implantation of allogeneic Ad-MSCs around lacrimal glands has been found as an effective therapeutic alternative to treat dogs with KCS. These results could reinforce a good effective solution to be extrapolated to future studies in human.

For Veterinarians only

For Veterinarians only

Ask your veterinarian for the price of a stem cell injection at his clinic.

Product Pipeline

Range Product Development & optimization Proof of Concept Pilot study Industrialisation /
Manufacturing
Pivotal study Approval Marketing Launch

CANIPREN

VBX-01
Canine osteoarthritis

CA0102
Atopic dermatitis

CA0103
Atopic dermatitis
Chronic
Inflammatory
Bowel
Disease

Range Product Development & optimization Proof of Concept Pilot study Industrialisation /
Manufacturing
Pivotal study Approval Marketing Launch

FELIPREN

FE0101
Gingivostomatitis

FE0102
Chronic kidney
failure

FE0103
Feline arthrosis

Range Product Development & optimization Proof of Concept Pilot study Industrialisation /
Manufacturing
Pivotal study Approval Marketing Launch

EQUIPREN
OMBISTEM

EQ0101
Equine arthrosis